Redhill Biopharma (RDHL) Earning Somewhat Favorable News Coverage, Analysis Shows
News stories about Redhill Biopharma (NASDAQ:RDHL) have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Redhill Biopharma earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.3316177763035 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern’s analysis:
- Redhill Biopharma: Successful Phase II With Bekinda For IBS-D – Investing.com (investing.com)
- Redhill Biopharma Ltd. (RDHL) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- -$0.65 Earnings Per Share Expected for Redhill Biopharma Ltd. (RDHL) This Quarter (americanbankingnews.com)
- Redhill Biopharma Ltd. (RDHL) Downgraded by Zacks Investment Research (americanbankingnews.com)
Several brokerages recently issued reports on RDHL. Zacks Investment Research lowered shares of Redhill Biopharma from a “buy” rating to a “hold” rating in a research report on Friday, November 24th. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of Redhill Biopharma in a research report on Tuesday, November 21st. Roth Capital cut their target price on shares of Redhill Biopharma from $27.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, November 14th. Seaport Global Securities began coverage on shares of Redhill Biopharma in a research report on Friday, October 6th. They set a “buy” rating and a $19.00 target price for the company. Finally, UBS began coverage on shares of Redhill Biopharma in a research report on Wednesday, September 13th. They set a “reduce” rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $21.10.
Redhill Biopharma (RDHL) opened at $5.03 on Thursday. Redhill Biopharma has a 12-month low of $4.82 and a 12-month high of $12.09.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.